Overview Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or 2 Diabetes Status: Completed Trial end date: 2003-11-26 Target enrollment: Participant gender: Summary This trial is conducted in Asia. The aim of this trial is to investigate the efficacy of biphasic insulin aspart 30 on postprandial glycaemic control. Phase: Phase 3 Details Lead Sponsor: Novo Nordisk A/STreatments: Biphasic InsulinsInsulinInsulin AspartInsulin aspart, insulin aspart protamine drug combination 30:70Insulin degludec, insulin aspart drug combinationInsulin, Globin ZincInsulin, IsophaneInsulin, Long-Acting